Lilly’s Zepbound Trims More Belly Fat Than Novo’s Wegovy 

In This Article

• Zepbound Beats Wegovy for Weight Loss 
• About Zepbound and Wegovy

Two of the leading drug companies making weight loss drugs are in competition in the market, and experiments and surveys have been done on multiple people. This is the first time these two companies came head-to-head for such activity, and Eli Lilly won it.

Weight gain is one of the leading causes of serious illnesses and diseases around the world, and weight loss is a difficult task. The medical industry is using safe and efficient ways to deal with such issues, and Eli Lilly and Novo are the prominent ones.

Zepbound Beats Wegovy for Weight Loss 

Eli Lilly’s weight loss drug Zepbound stood head-to-head with Novo’s Wegovy, and the winner is Zepbound. The study was funded by Eli Lilly, and this shows the confidence of the company in the medicine. The results were published in the New England Journal of Medicine on Sunday.

The medicine is tirzepatide, which, on average, causes a weight loss of 50 pounds, which is a big achievement. On the other hand, Novo’s product is Nordisk’s semaglutide, also known as Wegovy. On average, it loses only 33 pounds, which is almost half of what the winner loses.

The trial was done on a large number of people, and according to the records, there were 751 participants. All of these were considered obese or overweight. The experts chose the participants that are struggling with the disease caused by the obesity.

The trial lasted for 72 weeks, and those who took the Zepbound lost 20% of their body weight; that is more than they were expecting. On the other side, Wegovy users lose 14% of their weight, which is 16% less than the winning solution.

On this, Eli Lilly’s senior vice president of global medical affairs, named Leonard Glass said,

These data confirm Zepbound as a leading treatment option for people living with obesity and equip healthcare providers with critical insights to make well-informed treatment decisions as part of a comprehensive obesity care plan

In the medical industry, artificial intelligence is helping experts to perform research and create useful products. Similarly, AI is one of the most promising techniques for web solutions to make them advanced and more prominent in the market.

Weborik Hub is presenting the remarkable services for the integration of AI features in web solutions. As a result, the websites and apps work more efficiently and present advanced features and intelligent functionality.

About Zepbound and Wegovy

Zepbound and Wegovy drugs are a new class of medication that mimics the gut and brain hormones. These hormones regulate the appetite, and the person gets the feeling of fullness. According to the director of the Comprehensive Weight Control Center at Weill Cornell Medicine, Dr. Louis Aronne, Wegovy targets one hormone, but Zepbound targets two: GLP-1 and GIP.

He says,

Two drugs together can produce better weight loss

These medicines stimulate the proper functioning of the body and are used for better health conditions.

The point of these medications is to improve health. The majority of people won’t need the most effective medication.

Both these companies got the better response from the buyers after this test.